PT-141 (bremelanotide)
PT141 · Bremelanotide
PT-141 is a name associated with bremelanotide, a cyclic melanocortin peptide analogue. It is related to, but chemically distinct from, Melanotan II.
Reviewed September 2026
- Residues
- 7. verified: 7 main-chain residues in the reference cyclic peptide, including noncanonical norleucine and D-Phe.
- Average mass
- 1,025.2 Da. verified: Reference form: Bremelanotide/PT-141 reference cyclic peptide (free peptide moiety); not its acetate salt and not the distinct C-terminally amidated Melanotan II.; formula C50H68N14O10. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 7 |
|---|---|
| Average mass | 1,025.2 Da |
| pI | Not established |
| Aliases | PT141, Bremelanotide |
|---|---|
| Research area | Endocrine |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Bremelanotide/PT-141 reference cyclic peptide (free peptide moiety); not its acetate salt and not the distinct C-terminally amidated Melanotan II. Reference only, not a sold-lot measurement.
- Residues: 7 (verified). 7 main-chain residues in the reference cyclic peptide, including noncanonical norleucine and D-Phe. Residues source 1
- Average mass: 1,025.2 Da (verified). Reference form: Bremelanotide/PT-141 reference cyclic peptide (free peptide moiety); not its acetate salt and not the distinct C-terminally amidated Melanotan II.; formula C50H68N14O10. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Cyclic modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: PT141. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- PubChem: bremelanotide, CID 9941379. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
- Long-term safety and efficacy of bremelanotide: RECONNECT extension. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About PT-141 (bremelanotide)
Identity and context
The reference structure includes a ring, non-standard residue chemistry and defined stereochemistry. Terminal-group differences between related melanocortin analogues matter. This page therefore does not reduce bremelanotide to an unmodified linear peptide sequence.
Reference classification
Cyclic modified peptide. The linked catalogue product is PT141. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the cyclic structure, terminal chemistry and full chemical form. Preserve the difference between PT141, Melanotan I and Melanotan II when matching documentation to a catalogue item.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | The cited RECONNECT extension followed selected participants from earlier controlled studies of bremelanotide in premenopausal women with hypoactive sexual desire disorder. It was an open-label extension with descriptive analyses; nausea, flushing and headache were reported among adverse events. | Source context |
| What cannot be inferred | An extension study has selection and interpretation limits and is not a trial of the Aminos PT141 product. Results for a defined pharmaceutical formulation do not authenticate or establish clinical suitability of a separate research preparation. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- PubChem: bremelanotide, CID 9941379Primary source for the reference discussion; not lot-specific product evidence.
- Long-term safety and efficacy of bremelanotide: RECONNECT extensionPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.